Avantor AI Stock Analysis
Want to see AVTR full AI Analyst Report?
Avantor (AVTR) AI Stock Analysis
Avantor
(NYSE:AVTR)
AVTR scores as moderately attractive, led by improving fundamentals (profitability and leverage stabilizing with solid cash generation) and supportive technical momentum (price above key moving averages with positive MACD). The earnings call adds confidence via raised guidance and strong free cash flow, while the main constraint on the score is valuation risk given the high P/E and no dividend support.
Avantor Key Performance Indicators (KPIs)
Revenue by SegmentShows how much each business segment contributes to total revenue, indicating the company’s diversification and which segments are leading growth or facing headwinds.
Avantor resegmented reporting in 2026, shifting legacy Laboratory Solutions/Bioscience Production into VWR Distribution & Services and Bioscience & Medtech Products—an important change because VWR is now the larger, accelerating revenue engine (returned to organic growth) while BMP carries discrete, near‑term order normalization and electronic‑materials headwinds despite a healthy book‑to‑bill. Management’s raised guidance and cash generation hinge on VWR momentum and BMP converting backlog in H2; watch those two drivers plus FX and leverage progress for upside.
Avantor (AVTR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.38B
- Dividend Yield
- ―
- Average Volume (3M)
- 8.69M
- Price to Earnings (P/E)
- 30.7
- Beta (1Y)
- 0.89
- Revenue Growth
- 0.92%
- EPS Growth
- ―
- Country
- US
- Employees
- 13,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Avantor Business Overview & Revenue Model
Company Description
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array...
How the Company Makes Money
Avantor primarily makes money by selling products and services used in laboratory research, testing, and biopharmaceutical manufacturing. Its revenue is largely generated from (1) consumables and repeat-purchase items (e.g., chemicals, reagents, lab...
Avantor Earnings Call Summary
The call was strongly constructive. Avantor reported a return to organic growth, outperformance in both revenue and adjusted EPS, positive performance in VWR and BMP, robust free cash flow, lower leverage, improved order trends, and raised full-year guidance. The main challenges were mix and inflationary margin pressure, foreign-exchange headwinds, BMP comparison effects, pricing that remains below inflation, and a lagging European market. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Avantor raised its organic revenue growth outlook to a range of 0.75 to 1.25%, with Q4 organic revenue growth implied at 2.5 to 4.5%; foreign exchange is expected to be a headwind of 150 basis points to reported revenue in Q4 and contribute approximately 75 basis points to full year reported revenue growth. VWR is expected to grow mid single digits in Q4, while BMP is expected to deliver year over year organic growth that is flat to slightly positive, reflecting approximately 400 basis points of headwind from discrete comparisons, with modest sequential growth from Q3 to Q4. Adjusted EBITDA margin guidance remains unchanged and is expected to expand modestly from Q3 to Q4; the adjusted effective tax rate is expected to be between 22% and 22.5%, weighted average diluted share count is expected to be 679 million shares, adjusted EPS guidance is $0.81 to $0.83, and free cash flow guidance is between $520 million and $550 million in 2026, with the adjusted net leverage ratio expected to be below 3x by year end.
Avantor Financial Statement Overview
Summary
Financials look stabilized rather than fully re-accelerating: TTM profitability returned to positive territory after a weak 2025, leverage is improving, and operating/free cash flow remain consistently positive. Offsetting this, multi-year revenue has been flat-to-down and margins are meaningfully below 2022–2024 levels, with limited near-term cash-flow momentum.
Income Statement
60NeutralBalance Sheet
68PositiveCash Flow
66Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.64B | 6.55B | 6.78B | 6.97B | 7.51B | 7.39B |
| Gross Profit | 2.10B | 2.14B | 2.28B | 2.36B | 2.60B | 2.50B |
| EBITDA | 909.30M | 138.70M | 1.48B | 1.10B | 1.52B | 1.35B |
| Net Income | 337.20M | -530.20M | 711.50M | 321.10M | 686.50M | 572.60M |
Balance Sheet | ||||||
| Total Assets | 11.63B | 11.79B | 12.11B | 12.97B | 13.46B | 13.90B |
| Cash, Cash Equivalents and Short-Term Investments | 464.30M | 365.40M | 261.90M | 262.90M | 372.90M | 301.70M |
| Total Debt | 3.68B | 3.95B | 4.06B | 5.54B | 6.29B | 7.02B |
| Total Liabilities | 5.79B | 6.23B | 6.16B | 7.72B | 8.61B | 9.70B |
| Stockholders Equity | 5.84B | 5.57B | 5.96B | 5.25B | 4.86B | 4.20B |
Cash Flow | ||||||
| Free Cash Flow | 439.20M | 495.00M | 692.00M | 723.60M | 710.20M | 842.50M |
| Operating Cash Flow | 584.70M | 623.80M | 840.80M | 870.00M | 843.60M | 953.60M |
| Investing Cash Flow | -148.20M | -130.50M | 438.90M | -143.70M | -109.60M | -4.12B |
| Financing Cash Flow | -217.10M | -409.40M | -1.28B | -843.70M | -648.70M | 3.22B |
Avantor Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTR, the sentiment is Negative. The current price of 15.32 is below the 20-day moving average (MA) of 16.17, below the 50-day MA of 15.71, and above the 200-day MA of 11.41, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 42.36 is Neutral, neither overbought nor oversold. The STOCH value of 37.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVTR.
Avantor Risk Analysis
Avantor disclosed 39 risk factors in its most recent earnings report. Avantor reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAvantor Peers Comparison
Overall Rating
WST78Outperform
AVTR68Neutral
AZTA63Neutral
STVN55Neutral
RGEN54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $29.10B | 46.46 | 21.08% | 0.22% | 12.60% | 32.05% | |
| 68Neutral | $10.38B | 30.70 | 5.96% | ― | 0.92% | ― | |
| 63Neutral | $2.07B | -13.00 | -10.81% | ― | 4.65% | -196.27% | |
| 55Neutral | $4.24B | 27.86 | 9.07% | 0.40% | 11.99% | 4.96% | |
| 54Neutral | $10.41B | -779.19 | -0.56% | ― | 13.80% | -811.00% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AVTR | Avantor | 15.32 | 4.18 | 37.52% | |
| AZTA | Azenta, Inc. | 47.22 | 17.80 | 60.50% | |
| RGEN | Repligen | 162.78 | 9.72 | 6.35% | |
| WST | West Pharmaceutical Services, Inc. | 417.80 | 158.43 | 61.08% | |
| STVN | Stevanato Group Spa | 15.53 | -5.23 | -25.21% |
Avantor Corporate Events
Avantor Names Todd Garner as New Chief Financial Officer
PositiveOn September 21, 2026, Avantor, Inc. appointed Todd Garner as Executive Vice President and Chief Financial Officer, with Garner joining the Executive Leadership Team as the company’s principal financial officer. The move ends the interim CFO tenure o...
Avantor Appoints Todd Garner as New Chief Financial Officer
PositiveOn September 21, 2026, Avantor announced that Todd Garner was appointed Executive Vice President and Chief Financial Officer, joining the executive leadership team and serving as the company’s principal financial officer. He will oversee global finan...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
